z-logo
open-access-imgOpen Access
Primary cardiac angiosarcoma: modern methods of diagnosis and treatment
Author(s) -
Д А Сарачан,
А В Скребцов,
Е. А. Захарьян,
Д. C. Собинов
Publication year - 2020
Publication title -
rossijskij kardiologičeskij žurnal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.141
H-Index - 14
eISSN - 2618-7620
pISSN - 1560-4071
DOI - 10.15829/1560-4071-2020-3824
Subject(s) - medicine , radiology , pazopanib , bevacizumab , magnetic resonance imaging , angiosarcoma , doxorubicin , positron emission tomography , chemotherapy , sorafenib , oncology , cancer , sunitinib , hepatocellular carcinoma
The review is dedicated to such a rare disease as primary cardiac angiosarcoma (PCA). The following imaging methods are used for its diagnosing: transthoracic and transesophageal echocardiography, computed tomography, positron emission tomography and magnetic resonance imaging. To verify the diagnosis, a biopsy with cytological and immunohistochemical analysis is performed. The symptoms of PCA is non-specific and often manifests itself only in the late stages, which leads to a significant deterioration of prognosis. Treatment of PCA requires a multifaceted approach. It mainly involves the achievement of a curative resection (R0 resection). Regarding chemotherapy, neoadjuvant therapy with doxorubicin and ifosfamide is effective. In addition to these agents, cyclophosphamide, anthracycline, vincristine and others are used. Today, the use of targeted therapy with imatinib, sorafenib, pazopanib, and bevacizumab is promising. However, it requires further analysis. The article also describes other therapy methods using a beta-blockers and radiation exposure.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here